Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone

Bone

Volumn 48, Issue 6, 2011, Pages 1354-1361

  Li, Xin ^a   Liao, Jinhui ^a   Park, Serk In ^a   Koh, Amy J ^a   Sadler, William D ^a   Pienta, Kenneth J ^b   Rosol, Thomas J ^c   McCauley, Laurie K ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Anti resorptive; Bone resorption; Calcium; Osteoprotegrin (OPG); Prostate tumor; Zoledronic acid (ZA)

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCIUM; OSTEOPROTEGERIN; OSTEOPROTEGERIN FC; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE METASTASIS; CALCIUM BLOOD LEVEL; CALCIUM TRANSPORT; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROSTATE CANCER; TIBIA; TUMOR GROWTH;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CELL DIVISION; CELL LINE, TUMOR; DIPHOSPHONATES; DOGS; IMIDAZOLES; MALE; MICE; MICE, NUDE; OSTEOCLASTS; PROSTATIC NEOPLASMS;

EID: 79955901635     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.03.687     Document Type: Article

References (40)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Schneider A., Kalikin L.M., Mattos A.C., Keller E.T., Allen M.J., Pienta K.J., et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005, 146:1727-1736.
3. Liao J., Schneider A., Datta N.S., McCauley L.K. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 2006, 66:9065-9073.
4. Zheng Y., Zhou H., Modzelewski J.R., Kalak R., Blair J.M., Seibel M.J., et al. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone. Cancer Res 2007, 67:9542-9548.
5. Kollet O., Dar A., Lapidot T. The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol 2007, 25:51-69.
6. Dunn L.K., Mohammad K.S., Fournier P.G., McKenna C.R., Davis H.W., Niewolna M., et al. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 2009, 4:e6896.
7. Hirbe A.C., Rubin J., Uluckan O., Morgan E.A., Eagleton M.C., Prior J.L., et al. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci U S A 2007, 104:14062-14067.
8. Li X., Loberg R., Liao J., Ying C., Snyder L.A., Pienta K.J., et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 2009, 69:1685-1692.
9. Lu Y., Cai Z., Xiao G., Keller E.T., Mizokami A., Yao Z., et al. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 2007, 67:3646-3653.
10. Mundy G.R. Mechanisms of bone metastasis. Cancer 1997, 80:1546-1556.
11. Russell M.R., Jamieson W.L., Dolloff N.G., Fatatis A. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene 2009, 28:412-421.
12. Brown H.K., Holen I. Anti-tumour effects of bisphosphonates-what have we learned from in vivo models?. Curr Cancer Drug Targets 2009, 9:807-823.
13. Clezardin P., Fournier P., Boissier S., Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 2003, 10:173-180.
14. Fournier PG, Stresing V, Ebetino FH, Clezardin P. How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia 12:571-8.
15. Hiraga T., Williams P.J., Ueda A., Tamura D., Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004, 10:4559-4567.
16. Li Y.Y., Chang J.W., Chou W.C., Liaw C.C., Wang H.M., Huang J.S., et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 2008, 59:180-191.
17. Ory B., Heymann M.F., Kamijo A., Gouin F., Heymann D., Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005, 104:2522-2529.
18. Zheng Y., Zhou H., Brennan K., Blair J.M., Modzelewski J.R., Seibel M.J., et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007, 40:471-478.
19. LeRoy B.E., Thudi N.K., Nadella M.V., Toribio R.E., Tannehill-Gregg S.H., van Bokhoven A., et al. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate 2006, 66:1213-1222.
20. Koh A.J., Demiralp B., Neiva K.G., Hooten J., Nohutcu R.M., Shim H., et al. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 2005, 146:4584-4596.
21. Pettway G.J., McCauley L.K. Ossicle and vossicle implant model systems. Methods Mol Biol 2008, 455:101-110.
22. Lin D.L., Tarnowski C.P., Zhang J., Dai J., Rohn E., Patel A.H., et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001, 47:212-221.
23. Rohanizadeh R., Swain M.V., Mason R.S. Gelatin sponges (Gelfoam) as a scaffold for osteoblasts. J Mater Sci Mater Med 2008, 19:1173-1182.
24. Ruifrok A.C., Johnston D.A. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001, 23:291-299.
25. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
26. Capparelli C., Morony S., Warmington K., Adamu S., Lacey D., Dunstan C.R., et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 2003, 18:852-858.
27. Kostenuik P.J., Bolon B., Morony S., Daris M., Geng Z., Carter C., et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 2004, 34:656-664.
28. Skinner H.G., Schwartz G.G. Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 2008, 17:2302-2305.
29. Skinner H.G., Schwartz G.G. A prospective study of total and ionized serum calcium and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:575-578.
30. Johannesen J., Briody J., McQuade M., Little D.G., Cowell C.T., Munns C.F. Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease. Bone 2009, 45:898-902.
31. Plotkin H., Rauch F., Zeitlin L., Munns C., Travers R., Glorieux F.H. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 2003, 88:4569-4575.
32. Siris E.S., Lyles K.W., Singer F.R., Meunier P.J. Medical management of Paget's disease of bone: indications for treatment and review of current therapies. J Bone Miner Res 2006, 21(Suppl 2):94-98.
33. Yang M., Burton D.W., Geller J., Hillegonds D.J., Hastings R.H., Deftos L.J., et al. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Clin Cancer Res 2006, 12:2602-2606.
34. Bronner F. Extracellular and intracellular regulation of calcium homeostasis. ScientificWorldJournal 2001, 1:919-925.
35. Mastrandrea L.D., Albini C.H. Bisphosphonate treatment of tumor-induced hypercalcemia in a toddler: case report and review of related literature. Endocr Pract 2006, 12:670-675.
36. Waked A., Geara A., El-Imad B. Hypercalcemia, metabolic alkalosis and renal failure secondary to calcium bicarbonate intake for osteoporosis prevention - 'modern' milk alkali syndrome: a case report. Cases J 2009, 2:6188.
37. Ravn P. Bisphosphonates for prevention of postmenopausal osteoporosis. Dan Med Bull 2002, 49:1-18.
38. Corey E., Brown L.G., Quinn J.E., Poot M., Roudier M.P., Higano C.S., et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003, 9:295-306.
39. Brubaker K.D., Brown L.G., Vessella R.L., Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006, 6:15.
40. Miwa S., Mizokami A., Keller E.T., Taichman R., Zhang J., Namiki M. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 2005, 65:8818-8825.